Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation

American Journal of Surgical Pathology

Volumn 35, Issue 6, 2011, Pages 878-882

  Shi, Min ^a   Fraire, Armando E ^a   Chu, Peiguo ^b   Cornejo, Kristine ^a   Woda, Bruce A ^a   Dresser, Karen ^a   Rock, Kenneth L ^a   Jiang, Zhong ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

diagnostic biomarker; IMP3; malignant mesothelioma; reactive mesothelial proliferations

Indexed keywords

IMP3 PROTEIN, HUMAN; RNA BINDING PROTEIN; TUMOR MARKER;

ARTICLE; CELL PROLIFERATION; DIFFERENTIAL DIAGNOSIS; EPITHELIUM; HUMAN; HYPERPLASIA; MESOTHELIOMA; METABOLISM; PATHOLOGY; PERITONEUM; PERITONEUM TUMOR; PLEURA; PLEURA TUMOR;

CELL PROLIFERATION; DIAGNOSIS, DIFFERENTIAL; EPITHELIUM; HUMANS; HYPERPLASIA; MESOTHELIOMA; PERITONEAL NEOPLASMS; PERITONEUM; PLEURA; PLEURAL NEOPLASMS; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 79958003727     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318218985b     Document Type: Article

References (35)

1. Archer VE, Rom WN. Trends in mortality of diffuse malignant mesothelioma of pleura. Lancet. 1983;2:112-113. (Pubitemid 13066595)
2. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43:231-238. (Pubitemid 37115056)
3. Cagle PT, Brown RW, Lebovitz RM. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum Pathol. 1994;25:443-448.
4. Cai YC, Roggli V, Mark E, et al. Transforming growth factor alpha and epidermal growth factor receptor in reactive and malignant mesothelial proliferations. Arch Pathol Lab Med. 2004;128:68-70. (Pubitemid 38049570)
5. Findeis-Hosey JJ, Xu H. The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. Human Pathology. 2010;42:303-314.
6. Hoffmann NE, Sheinin Y, Lohse CM, et al. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 2008;112:1471-1479. (Pubitemid 351441159)
7. Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009;133:1317-1331.
8. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006;7:556-564. (Pubitemid 43923666)
9. Jiang Z, Chu PG, Woda BA, et al. Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res. 2008; 14:5579-5584.
10. Jiang Z, Lohse CM, Chu PG, et al. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer. 2008;112:2676-2682. (Pubitemid 351969211)
11. Kafiri G, Thomas DM, Shepherd NA, et al. p53 expression is common in malignant mesothelioma. Histopathology. 1992;21:331-334.
12. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20:215-220. (Pubitemid 46422176)
13. King J, Thatcher N, Pickering C, et al. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology. 2006;49:561-568. (Pubitemid 44924287)
14. Krismann M, Muller KM, Jaworska M, et al. Pathological anatomy and molecular pathology. Lung Cancer. 2004;45(suppl 1):S29-S33. (Pubitemid 38917110)
15. Leigh J, Davidson P, Hendrie L, et al. Malignant mesothelioma in Australia, 1945-2000. Am J Ind Med. 2002;41:188-201. (Pubitemid 34195157)
16. Liao B, Hu Y, Herrick DJ, et al. The RNA-binding Protein IMP-3 Is a Translational Activator of Insulin-like Growth Factor II Leader-3 mRNA during Proliferation of Human K562 Leukemia Cells. J Biol Chem. 2005;280:18517-18524. (Pubitemid 41389102)
17. Lu D, Vohra P, Chu PG, et al. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia. Am J Surg Pathol. 2009;33:521-525.
18. Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene. 1997;14:2729-2733. (Pubitemid 27283112)
19. Mueller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 1999;88:95-99. (Pubitemid 29467415)
20. Nielsen FC, Nielsen J, Christiansen J. A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl. 2001;234:93-99. (Pubitemid 33043632)
21. Nielsen J, Christiansen J, Lykke-Andersen J, et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999;19:1262-1270. (Pubitemid 29046868)
22. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer. 1999;79:666-672. (Pubitemid 29046253)
23. Ramael M, Lemmens G, Eerdekens C, et al. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol. 1992;168:371-375. (Pubitemid 23013253)
24. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591-1603. (Pubitemid 41434638)
25. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397-408. (Pubitemid 41073959)
26. Sato A, Torii I, Okamura Y, et al. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol. 2010;23:1458-1466.
27. Sitnikova L, Mendese G, Liu Q, et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 2008;14:1701-1706. (Pubitemid 351469454)
28. Takeda M, Kasai T, Enomoto Y, et al. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int. 2010;60:395-399.
29. Vikesaa J, Hansen TV, Jonson L, et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J. 2006;25: 1456-1468.
30. Wang T, Hopkins D, Schmidt C, et al. Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis. Oncogene. 2000;19:1519-1528. (Pubitemid 30175673)
31. Wolanski KD, Whitaker D, Shilkin KB, et al. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer. 1998;82:583-590. (Pubitemid 28112999)
32. Yaniv K, Yisraeli JK. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene. 2002;287:49-54. (Pubitemid 34460566)
33. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29:188-195. (Pubitemid 40170636)
34. Zhang JY, Chan EK, Peng XX, et al. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med. 1999;189:1101-1110. (Pubitemid 29169827)
35. Zheng W, Yi X, Fadare O, et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008;32:304-315. (Pubitemid 351172146)